Serial troponin measurements could predict cardiovascular ri
The researchers analyzed data from 3318 participants of the WOSCOPS (West of Scotland Coronary Prevention Study) trial, in which men with raised low-density lipoprotein (LDL) cholesterol and no history of myocardial infarction were randomly assigned to receive pravastatin or placebo.

They found that participants with the highest quartile of plasma troponin concentration (?5.2 ng/L) at baseline had a significantly higher risk for nonfatal myocardial infarction or death from coronary heart disease (CHD) at 5 and 15 years than those in the lowest quartile (?3.1 ng/L), with hazard ratios (HRs) of 2.27 and 1.54, respectively.

Furthermore, men receiving pravastatin experienced a 19% reduction in troponin levels at 1 year, compared with a 6% reduction among participants receiving placebo....